Physician profile
Deepnarayan Tiwarri
NPI 1649217464
$14,983.08
in general payments reported to CMS, 2019-2025
73 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,467 · 2020: $593 · 2021: $252 · 2022: $1,881 · 2023: $4,905 · 2024: $2,054 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,011 · Honoraria: $1,167 · Travel and Lodging: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,011.27 |
| Honoraria | $1,166.66 |
| Travel and Lodging | $612.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $2,461.32 | 2019-2023 | Tavalisse, Rezlidhia |
| Pharmacosmos Therapeutics INC. | $1,861.86 | 2022-2025 | Monoferric |
| Pfizer INC. | $1,045.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $718.45 | 2019-2025 | |
| Janssen Biotech, INC. | $672.03 | 2019-2025 | Imbruvica, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $666.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $554.50 | 2019-2025 | Opdivo, Eliquis, Augtyro |
| Daiichi Sankyo INC. | $491.38 | 2020-2025 | Injectafer, Enhertu, Vanflyta |
| Genzyme Corporation | $358.30 | 2019-2025 | |
| Abbvie INC. | $344.46 | 2019-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $314.50 | 2022-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $287.23 | 2019-2025 | Xospata, Padcev, Xtandi |
| Astrazeneca Pharmaceuticals Lp | $279.28 | 2020-2025 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $262.24 | 2022-2025 | Venclexta, Tecentriq, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $261.33 | 2019-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.27 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Celgene Corporation | $235.14 | 2022-2025 | Reblozyl, Opdualag, Opdivo |
| Eisai INC. | $225.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.64 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $212.79 | 2022-2025 | Fruzaqla, Alunbrig |
| Incyte Corporation | $178.78 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Emd Serono, INC. | $145.96 | 2019-2025 | |
| Tersera Therapeutics LLC | $145.13 | 2019-2025 | Xermelo, Zoladex |
| Mirati Therapeutics, INC. | $140.66 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $140.16 | 2022-2025 | Besremi |
| Array Biopharma INC | $138.25 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $136.21 | 2019-2023 | Tukysa, Tivdak |
| Regeneron Healthcare Solutions, INC. | $131.85 | 2019-2024 | Libtayo |
| Exelixis INC. | $121.86 | 2022-2023 | Cabometyx |
| Spectrum Pharmaceuticals INC. | $121.42 | 2023-2025 | Rolvedon |
| Puma Biotechnology, INC. | $119.21 | 2019-2025 | |
| Gilead Sciences, INC. | $117.35 | 2021-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $117.01 | 2020-2024 | Ultomiris |
| Kite Pharma, INC. | $112.69 | 2020-2025 | Yescarta |
| Beigene USA, INC. | $83.24 | 2022-2024 | Brukinsa |
| Adaptive Biotechnologies Corporation | $82.95 | 2023-2025 | Clonoseq |
| Adc Therapeutics America, INC. | $78.26 | 2022-2024 | |
| Lilly USA, LLC | $70.90 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Heron Therapeutics, INC. | $68.59 | 2023 | Sustol, Cinvanti |
| Agios Pharmaceuticals, INC. | $63.47 | 2019-2024 | Pyrukynd |
| Servier Pharmaceuticals LLC | $61.36 | 2022-2025 | |
| Blueprint Medicines Corporation | $60.74 | 2022 | |
| Kyowa Kirin, INC. | $59.88 | 2019-2024 | Poteligeo |
| Coherus Oncology, INC. | $57.67 | 2022-2023 | |
| Foundation Medicine, INC. | $48.62 | 2019-2021 | |
| Morphosys, US INC. | $48.44 | 2023-2024 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $42.34 | 2019-2024 | Onivyde, Somatuline Depot |
| Immunocore Limited | $38.18 | 2025 | Kimmtrak |
| Sumitomo Pharma America, INC. | $36.44 | 2023 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.92 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $35.77 | 2020-2021 | |
| Stemline Therapeutics INC. | $34.78 | 2023 | Orserdu |
| Beone Medicines USA, INC. | $32.37 | 2025 | Brukinsa |
| Genmab U.S., INC. | $28.49 | 2023 | Epkinly |
| Dendreon Pharmaceuticals LLC | $26.86 | 2019 | |
| Aveo Pharmaceuticals, INC. | $26.08 | 2025 | |
| Geron Corporation | $24.91 | 2025 | Rytelo |
| Myovant Sciences INC. | $24.09 | 2022 | |
| Mylan Institutional INC. | $23.43 | 2019 | |
| Cycle Pharmaceuticals INC | $22.29 | 2025 | Phyrago |
| Springworks Therapeutics, INC. | $21.98 | 2024 | Ogsiveo |
| Menarini Silicon Biosystems, INC. | $20.43 | 2024 | |
| Celltrion USA INC. | $19.73 | 2024 | Vegzelma |
| Tempus Ai, INC | $19.43 | 2024 | Xt Cdx |
| Janssen Pharmaceuticals, INC | $18.42 | 2019 | |
| Sobi, INC | $16.84 | 2023 | |
| Cti Biopharma Corp. | $15.20 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $14.87 | 2020 | |
| Shire North American Group INC | $14.76 | 2019 | |
| Myriad Genetic Laboratories, INC. | $14.51 | 2024 | Precisetumor |
| Horizon Therapeutics Plc | $11.85 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepnarayan Tiwarri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.